Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 88

Results For "EY"

3112 News Found

Merck Animal Health to acquire Elanco’s aqua business
News | February 07, 2024

Merck Animal Health to acquire Elanco’s aqua business

Bolsters Merck Animal Health’s position in the aqua industry with comprehensive approach to ensure fish health, welfare and sustainability in aquaculture, conservation and fisheries


Dr. Jitendra Singh launches multi-disciplinary post-doctoral courses in Bio-Sciences
News | February 06, 2024

Dr. Jitendra Singh launches multi-disciplinary post-doctoral courses in Bio-Sciences

1,000 Ph.D. students will be enrolled in the next five years to drive innovation in the critical healthcare sector


Mandaviya inaugurates 24 health infrastructure facilities across AIIMS
News | February 05, 2024

Mandaviya inaugurates 24 health infrastructure facilities across AIIMS

Delivers keynote address at the 4th convocation of AIIMS Jodhpur


Zydus Lifesciences launches Rexigo
News | February 01, 2024

Zydus Lifesciences launches Rexigo

This is the first and only oral once-a-day therapy for testosterone suppression in patients with advanced prostate cancer in India


AstraZeneca’s Imfinzi combination shows positive results in phase 3 liver cancer study
Diagnostic Center | January 31, 2024

AstraZeneca’s Imfinzi combination shows positive results in phase 3 liver cancer study

About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation


Enhertu granted Priority Review in the US for patients with metastatic HER2-positive solid tumours
Drug Approval | January 31, 2024

Enhertu granted Priority Review in the US for patients with metastatic HER2-positive solid tumours

Submission to be reviewed under FDA real-time oncology review and Project Orbis


Ascletis announces dosing of the first patient in Phase III clinical trial of ASC40
Diagnostic Center | January 30, 2024

Ascletis announces dosing of the first patient in Phase III clinical trial of ASC40

This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40


Eastman, SEG collaborate to launch INVU 10th anniversary collection with Tritan Renew
News | January 30, 2024

Eastman, SEG collaborate to launch INVU 10th anniversary collection with Tritan Renew

Tritan Renew, which is made with 50% certified recycled content derived from hard-to-recycle waste, performs like virgin-quality material


EMA validates Type II variation application for enfortumab vedotin with pembrolizumab for treatment of bladder cancer
Drug Approval | January 29, 2024

EMA validates Type II variation application for enfortumab vedotin with pembrolizumab for treatment of bladder cancer

Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival